Results 141 to 150 of about 50,906 (248)
Postherpetic Neuralgia: Mechanisms, Risk Factors, and Stratified Management—A Narrative Review
CNS Neuroscience &Therapeutics, Volume 32, Issue 7, July 2026.The incidence of PHN is increasing, posing a substantial public health burden. Its pathogenesis involves VZV reactivation, peripheral and central sensitization, and genetic susceptibility, with key risk factors including older age, severe acute pain, extensive rash, immunocompromise, comorbidities, and delayed treatment.
Fei Tang, Fukun Zhao
wiley +1 more source
Clinical Characteristics and Determinants of Complications in Pediatric Herpes Zoster Requiring Hospitalization. [PDF]
Children (Basel)Bilașco A +7 more
europepmc +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 109-113, July 2026.We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi +100 more
wiley +1 more source
Herpes Zoster Ophthalmicus Complicated by Optic Neuritis: Diagnostic and Therapeutic Challenges. [PDF]
CureusMeghana NR +3 more
europepmc +1 more source
Herpes zoster reactivation [PDF]
British Dental Journal, 2011 M, Ziaei, S A, Aslam, H, Ziaei
openaire +2 more sources
Interplay Between Infectious Diseases and the Endocrine System: An Overview and Clinical Insights
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.Infectious diseases can disrupt endocrine homeostasis through direct cytopathic injury, autoimmune dysregulation, or pathogen‐derived hormone‐like effects. Viruses and bacteria are the most frequent agents, whereas fungi and parasites contribute less commonly, even remaining clinically relevant, especially in the immunocompromised population.
Francesco Capoccia +4 more
wiley +1 more source
Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?
European Journal of Immunology, Volume 56, Issue 7, July 2026.Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni +4 more
wiley +1 more source